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OBJECTIVE
To determine whether, after adjustment for glycemia and other selected cova-
riates, hemoglobin A1c (HbA1c) differed among adults from six Hispanic/Latino
heritage groups (Central American, Cuban, Dominican, Mexican, Puerto Rican,
and South American) and between Hispanic/Latino and non-Hispanic white adults
without self-reported diabetes.
RESEARCH DESIGN AND METHODS
We performed a cross-sectional analysis of data from 13,083 individuals without
self-reported diabetes from six Hispanic/Latino heritage groups, enrolled from
2008 to 2011 in the Hispanic Community Health Study/Study of Latinos, and
2,242 non-Hispanic white adults enrolled during the 2007–2012 cycles of the
National Health and Nutrition Examination Survey. We compared HbA1c levels
among Hispanics/Latinos and between Hispanics/Latinos and non-Hispanic
whites before and after adjustment for age, sex, fasting (FPG) and 2-h post–oral
glucose tolerance test (2hPG) glucose, anthropometric measurements, and se-
lected biochemical and hematologic variables and after stratification by diabetes
status: unrecognized diabetes (FPG ‡7.1 mmol/L or 2hPG ‡11.2 mmol/L), pre-
diabetes (FPG 5.6–7.0 mmol/L or 2hPG 7.8–11.1 mmol/L), and normal glucose
tolerance (FPG <5.6 mmol/L and 2hPG <7.8 mmol/L).
RESULTS
Adjusted mean HbA1c differed significantly across all seven groups (P < 0.001).
Non-Hispanic whites had significantly lower HbA1c (P < 0.05) than each individual
Hispanic/Latino heritage group. Upon stratification by diabetes status, statisti-
cally significant differences (P < 0.001) in adjustedmean HbA1c persisted across all
seven groups.
CONCLUSIONS
HbA1c differs among Hispanics/Latinos of diverse heritage groups and between
non-Hispanic whites and Hispanics/Latinos after adjustment for glycemia and
other covariates. The clinical significance of these differences is unknown.
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Hemoglobin A1c (HbA1c) is a widely used
and accepted test for the diagnosis of
prediabetes and diabetes and the as-
sessment of glycemic control in patients
with diabetes (1).Due to the erythrocytes’
long lifetime and the slow, continuous,
and essentially irreversible characteristics
of the glycation process, HbA1c reflects
the average blood glucose concentration
for the preceding 2–3 months (1–4).
Prior studies have suggested and
demonstrated that HbA1c may vary
across racial/ethnic groups after adjust-
ment for plasma glucose levels (5–12).
In individuals without diabetes, two
analyses based on the National Health
Nutrition and Examination Survey
(NHANES) have reported higher HbA1c
levels among African Americans and
Mexican Americans compared with
non-Hispanic whites, and these differ-
ences persisted after adjustment for
age, sex, and anthropometric, biologi-
cal, or other covariates (7,8). Another
analysis based on NHANES demon-
strated differences in the increment in
HbA1c with each decade of age among
Mexican Americans, non-Hispanic blacks,
and non-Hispanic whites (9). In the Di-
abetes Prevention Program (10), non-
Hispanic white individuals with impaired
glucose tolerance had baseline HbA1c
levels 0.15–0.40% lower than individuals
from other racial/ethnic groups (includ-
ing Hispanics) before and after adjust-
ment for glucose levels and other
covariates. Another study of individuals
with diabetes reported HbA1c 0.3–0.8%
higher among those with ancestry other
than non-Hispanic white, despite the
fact that individuals from diverse racial/
ethnic groups had similar mean plasma
glucose levels (11).
The studies cited above reported dif-
ferences in HbA1c between Hispanics/
Latinos and non-Hispanic whites (with
or without diabetes) that accounted
for a variety of demographic, anthropo-
metric, and biological covariates (7–11).
Some of these studies specifically re-
ported differences in HbA1c between
non-Hispanic whites andMexican Amer-
icans (7–9). Other studies did not clearly
specify the composition of the Hispanic
group included or account for dif-
ferences by Hispanic/Latino heritage
(10,11). Considering the diverse genetic
admixture and socioeconomic, cultural,
geographic, history, andmigrationpatterns
that characterize each U.S. Hispanic/Latino
group, it cannot be assumed that the pre-
viously reported differences in HbA1c com-
paredwith non-Hispanicwhites apply to all
heritage groups. One study suggested that
HbA1cmay differ betweenDominicans and
other Hispanics/Latinoswith diabetes (her-
itage groups not specified) (12). However,
it is unknown whether this difference is
also observed among other Hispanic/
Latino heritage groupsdindependent
of glycemic statusdand what factors
may explain those differences.
Our analysis was based on data from
the baseline exam (2008–2011) of the
Hispanic Community Health Study/
Study of Latinos (HCHS/SOL) and the
NHANES 2007–2012 exam cycles. The
purpose of this analysis was to compare
mean HbA1c levels (before and after ad-
justment for selected covariates) among
six different Hispanic/Latino heritage
groups represented in the HCHS/SOL,
between Hispanics/Latinos (as a unitary
group) from the HCHS/SOL and non-
Hispanic whites from NHANES, and
between individual Hispanic/Latino
heritage groups and non-Hispanic whites
from NHANES. In addition, these compar-
isons would be further stratified by dia-
betes status category (normal glucose
tolerance [NGT], prediabetes, and unrec-
ognized diabetes) based on the American
Diabetes Association fasting plasma glu-
cose (FPG) and 2-h post–oral glucose
tolerance test plasma glucose (2hPG).
Understanding the potential differences
in HbA1c levels among different His-
panics/Latinos heritage groups would
have important clinical implications in
the use of this biomarker as a prediabetes
or diabetes diagnostic criterion and in the
monitoring of glycemic control in His-
panics/Latinos with diabetes.
RESEARCH DESIGN AND METHODS
Sampling and Examination in the
HCHS/SOL
The HCHS/SOL study methods and sam-
pling designs have previously been pub-
lished (13,14). Briefly, the HCHS/SOL is a
longitudinal, population-based study
with objectives including description
of the prevalence of selected chronic dis-
eases, identifying their risk and/or protec-
tive factors, and quantifying incidence of
fatal and nonfatal cardiovascular and pul-
monary events and all-cause mortality.
From March 2008 to June 2011, 16,415
persons, aged 18–74 years at the time of
screening,who self-identifiedasHispanics/
Latinos were examined. Participants were
recruited after a multistage probability
sampling of the communities in San Diego,
CA; Chicago, IL; Miami, FL; and the Bronx,
NY. The studywas approved by each of the
field centers’ and coordinating center’s in-
stitutional review boards. All enrolled indi-
viduals provided signed informed consent.
Approximately 93% of participants com-
pleted all interviews and tests.
In the HCHS/SOL, interviews (including
demographic and self-identified His-
panic/Latino heritage group), phlebot-
omy, processing of biospecimens, and
systolic blood pressure (SBP), diastolic
blood pressure (DBP), and anthropomet-
ric measurements (including BMI) were
performed by trained and certified staff
following a standard protocol (13). Fur-
ther detailed information is available at
www.cscc.unc.edu/hchs. Participants
were asked to consume only water and
necessarymedications after 10:00 P.M. the
night before the baseline visit and to re-
frain from smoking or physical activity be-
fore undergoing the fasting examination
procedures. The examination of pregnant
women was postponed until 3 months
postpartum. Individuals with other
chronic diseases or health conditions
were not excluded from participating. All
participants had FPG and HbA1c mea-
sured.After the initial venipuncture, those
without self-reported diabetes or FPG
#150 mg/dL (8.4 mmol/L) underwent a
standard 75-g 2-h oral glucose tolerance
test (OGTT), from which a 2hPG was ob-
tained. Therewere no other exclusions for
the OGTT.
Sampling and Examination in
NHANES
Using a 2-year-cycle multistage probabil-
ity samplingdesign, NHANES is conducted
to describe health conditions and disease
burden among a representative sample
of the U.S. civilian noninstitutionalized
population. During the 2007–2008,
2009–2010, and 2011–2012 cycles,
29,353 individuals were interviewed
and examined (15). Participants’ demo-
graphic and anthropometric character-
istics, SBP, DBP, and a blood sample were
obtained following a standard protocol
(16,17). All participants had HbA1c mea-
sured. FPG was obtained after an 8- to
24-h fast from individuals who were ran-
domly assigned to the morning examina-
tion; a 75-g OGTT was performed only on
these individuals to obtain 2hPG. Pregnant
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women and individuals with cancer, he-
mophilia, and other selected conditions
were included in the examination but
did not undergo the OGTT. Further
NHANES information is available at
http://www.cdc.gov/nchs/nhanes.htm.
Laboratory Methodology
Biospecimens for the select biochemical
variables in both the HCHS/SOL and
NHANES 2007–2012 cycles were pro-
cessed and analyzed by the Advanced
Research and Diagnostics Laboratory at
the University of Minnesota following
similar laboratory methodology and
quality-control protocols. Plasma glucose
was measured in EDTA-anticoagulated
plasma using a hexokinase enzymatic
method; alanine aminotransferase (ALT),
aspartate aminotransferase (AST), and
g-glutamyl aminotransferase (GGT) were
measured using an a-ketoglutaratic en-
zymatic method on a Roche Modular P
chemistry analyzer (Roche Diagnostics,
Indianapolis, IN). A hemogram (including
direct measures of hemoglobin [Hgb] and
mean corpuscular volume [MCV]) was
measured in EDTA whole blood using a
Sysmex XE-2100 instrument (Sysmex
America, Inc., Mundelein, IL). HbA1c was
measured in EDTA-anticoagulated whole
blood using a Tosoh G7 automated, non-
porous ion-exchange high-performance
liquid chromatography analyzer. Serum
insulin was measured using an ELISA as-
say (Mercodia AB, Uppsala, Sweden)
(from 1 October 2006 to 28 October 2009)
and a sandwich immunoassay method
with the Roche Elecsys 2010 analyzer
(Roche Diagnostics) (from 29 October
2009 to 30 June 2011). The glomerular
filtration rate was estimated (eGFR) using
the MDRD equation.
Definition of Hispanic/Latino Heritage
and Non-Hispanic White Categories
In the HCHS/SOL, participants were asked
what Hispanic/Latino group best de-
scribed their heritage (Central American,
Cuban,Dominican,Mexican,PuertoRican,
South American, more than one heri-
tage, or other) and, in addition to being
of Hispanic/Latino heritage, which other
categories they would use to describe
themselves (American Indian or Alaskan
Native, Asian, Native Hawaiian or Pacific
Islander, black or African American,
white, more than one race, unknown, or
not reported [13, www.cscc.unc.edu/
hchs]). Approximately 54% of HCHS/SOL
participants responded “unknown/refused”
or “multiracial” to thequestions about race.
Therefore, analyses based on racewere not
performed within the context of Hispanic/
Latinoheritage. In theNHANES, participants
were asked if they considered themselves
to be Hispanic or Latino, and what race or
races they considered themselves to be:
American Indian or Alaskan Native, Asian,
black or African American, native Hawaiian
or Pacific Islander, white, other, unknown,
or refused (16).
Definition of NGT, Prediabetes, and
Unrecognized Diabetes
To account for the possible confounding
effects of glycemic treatment on HbA1c,
we excluded participants with self-
reported diabetes and/or those who
were using antihyperglycemia medica-
tions from the analysis. Using FPG and
2hPG American Diabetes Association
criteria (1,18), we classified the remain-
ing participants as having unrecognized
diabetes (FPG $7.1 mmol/L or 2hPG
$11.2 mmol/L), prediabetes (impaired
fasting glucose, FPG 5.6–7.0 mmol/L,
or impaired glucose tolerance, 2hPG
7.8–11.1 mmol/L), or NGT (FPG ,5.6
mmol/L and 2hPG ,7.8 mmol/L). We
applied the same inclusion and exclu-
sion criteria, definitions of analysis
variables, and methods of statistical
analyses to the data obtained from both
HCHS/SOL and NHANES.
In HCHS/SOL, the total number of en-
rolled individuals was 16,415 (19). The
weighted mean age was 43.2 years (95%
CI 43.1–43.3), and ;21% were born in
the U.S. mainland, Puerto Rico, or other
U.S. territories. Of the total, 14,071 in-
dividuals reported no history of diabetes
or use of antihyperglycemia medica-
tions. Individuals with an eGFR ,60
mL/min/1.73m2 (N = 471), with age out-
side of the sampling required range (N =
5), or who self-identifiedwithmore than
one Hispanic/Latino heritage group (N =
437) were excluded. Also, 75 individuals
were excluded due to missing data on
HbA1c (N = 51) or Hispanic/Latino heri-
tage group data (N = 24). Therefore, a
total of 13,083 HCHS/SOL participants
who met all the criteria were included
in the analyses.
In NHANES, a total of 29,353 individ-
uals were examined during the 2007–
2008, 2009–2010, and 2011–2012 exams
(15). Of that total, 13,133 individuals
were examined in the morning in the
fasting state. Of these, 11,970 reported
no history of diabetes or use of antihy-
perglycemia medications. Individuals
with age outside of the HCHS/SOL age
range (N = 5,142), with an eGFR ,60
mL/min/1.73 m2 (N = 589), who self-
identified as other than non-Hispanic
white (N = 3,648), who did not undergo
anOGTT (N = 347), andwithmissingHbA1c
(N = 2) were excluded. A total of 2,242
non-Hispanic whites (49.7% males)
met all the criteria and were included
in the analyses.
Statistical Analysis
Weighted means (or percentages) and
95% CIs of characteristics were esti-
mated by Hispanic/Latino heritage
group, for everyone in HCHS/SOL, and
for non-Hispanic whites in NHANES after
merging of the two studies’ data sets.
The adjusted conditional marginal
means of HbA1c for each Hispanic/Latino
heritage group and non-Hispanic whites
were obtained from linear regression
models that included various covariates:
age, sex, BMI, FPG, 2hPG, fasting serum
insulin (FSI), Hgb, MCV, SBP, DBP, ALT,
AST, and GGT. The selection of these co-
variates was based on previously docu-
mented effect or relationship with HbA1c
(10,11,20). We repeated this analysis
stratifying by diabetes status categories
(NGT, prediabetes, and unrecognized di-
abetes). We conducted an omnibus test
for differences in Hispanic/Latino heri-
tage groups using a Wald F test. For
differences that were significant based
on the Wald F test, we conducted pair-
wise testing on every combination of
Hispanic/Latino heritage group. The
b-coefficients (95% CI) to predict HbA1c
and P values were obtained from
the merged HCHS/SOL and NHANES
samples. We also calculated the mean
HbA1c for each HCHS/SOL Hispanic/
Latino heritage group in unadjusted
linear regression models and with var-
ious levels of adjustment to investi-
gate the extent to which confounders
might explain unadjusted differences in
HbA1c.
The analyses described above were
also performed in each data set sepa-
rately. The results were very similar and
have been included in Supplementary
Tables 2–4 and Supplementary Fig. 1.
All statistical analyses were per-
formed using SAS, version 9.2, and
SAS-callable SUDAAN, version 11.0.1,
to account for the complex sampling
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designs, including unequal probabilities of
selection, oversampling, andnonresponse.
RESULTS
Of the 13,083 HCHS/SOL individuals
who met the inclusion criteria, 47.9%
were men, and the self-identified His-
panic/Latino heritage group breakdown
was 40.0% Mexican, 20.8% Cuban,
15.6% Puerto Rican, 10.3% Dominican,
7.9% Central American, and 5.4% South
American. Table 1 describes the demo-
graphic, anthropometric, andbiochemical
characteristics of HCHS/SOL participants
according to Hispanic/Latino heritage
group and non-Hispanic white partici-
pants from NHANES. All the characteris-
tics were statistically different (P, 0.05)
across groups.
Figure 1 illustrates all covariate–
adjusted mean (95% CI) HbA1c levels by
racial/ethnic group. The all covariate–
adjusted mean HbA1c was significantly
different among Hispanic/Latino heri-
tage groups (Wald F test, P , 0.001).
Based on pairwise comparisons, individ-
uals of Cuban heritage had significantly
(P , 0.05) lower adjusted mean HbA1c
levels (5.42% [95% CI 5.40–5.44]) com-
pared with other individual Hispanic/
Latino heritage groups, except those
of South American heritage (5.43%
[95% CI 5.40–5.46]). Based on pairwise
comparisons, non-Hispanic whites had
significantly lower (5.36% [95% CI
5.34–5.39]) adjusted mean HbA1c levels
compared with each Hispanic/Latino
heritage group (each P , 0.05). We
added diabetes status categories (based
on FPG and 2hPG) to the adjustment
model, and the differences across the
seven groups persisted and remained
statistically significant (data not shown).
In Table 2, we examined the differ-
ences in all covariate–adjusted mean
HbA1c levels by diabetes status cate-
gory. Within the NGT category, the all
covariate–adjusted mean HbA1c level
differed significantly according to His-
panic/Latino heritage groups (Wald F
test, P , 0.001). Pairwise comparisons
showed that this difference was attrib-
utable to significant differences (P ,
0.05) in HbA1c of Cuban versusMexican
and Puerto Rican heritage groups (ad-
justed mean HbA1c difference 0.04–0.05%
[National Glycohemoglobin Standard-
ization Program (NGSP) units]), and
Puerto Rican vs. South American heritage
groups (adjusted mean HbA1c difference
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0.04% [NGSP units]). The all covariate–
adjusted mean HbA1c of non-Hispanic
whites differed significantly from that
of individual Hispanic/Latino heritage
group (difference 0.05–0.10% [NGSP
units], each P , 0.05).
Within the prediabetes category, the
all covariate–adjusted mean HbA1c dif-
fered significantly according to His-
panic/Latino heritage group (Wald F
test, P , 0.001). The pairwise compari-
sons showed that this difference was
attributable to significant differences
(P , 0.05) in the HbA1c levels between
the Cuban and the Central American,
Dominican, and Mexican heritage
groups (difference 0.06–0.10% [NGSP
units]). The all covariate–adjusted
mean HbA1c also differed significantly
between non-Hispanic whites and each
Hispanic/Latino heritage group (differ-
ence 0.09–0.19% [NGSP units], each
P , 0.05).
Within the unrecognized diabetes
category, the all covariate–adjusted
mean HbA1c level differed significantly
among Hispanics/Latinos (Wald F test,
P, 0.001). This difference was attribut-
able to significant differences between
the Cuban and the Central American and
Puerto Rican heritage groups (differ-
ence 0.22–0.25% [NGSP units], P ,
0.05). The difference in all covariate–
adjusted HbA1c was significant between
non-Hispanic whites and Central Ameri-
can, Dominican, Mexican, and Puerto
Rican heritage groups (difference 0.25–
0.39% [NGSP units], each P , 0.05).
In a separate analysis, we compared
the all covariate–adjusted mean HbA1c
level of the HCHS/SOL (unitary group),
the HCH/SOL Mexican heritage group,
and the NHANES non-Hispanic whites
and performed a parallel analysis com-
paring the NHANES Mexican Americans,
NHANES Hispanics (unitary group), and
NHANES non-Hispanic whites. The
differences between HCHS/SOL and
NHANES non-Hispanic whites were sim-
ilar, statistically significant, and in the
same direction as the differences be-
tween NHANES Mexican American/His-
panic and non-Hispanic whites (data not
shown).
We estimated the b of the regression
model including all covariates associ-
ated with HbA1c for the combined
HCHS/SOL and NHANES data without
stratification by glycemic category
(Supplementary Table 1). A b indicates
the difference in HbA1c level for each
category of categorical variables (e.g.,
heritage, sex) or for each one-unit-
higher level of continuous variables
(e.g., BMI, FPG). The variable is consid-
ered statistically significant when the CI
does not contain zero. Age, sex, age * sex
interaction term, BMI, FPG, and 2hPG
were associated with HbA1c across all
seven groups. When the regression
model was evaluated in HCHS/SOL and
NHANES separately (Supplementary
Table 2), the same associations were
observed, except the age * sex interac-
tion, and FSI was associated with HbA1c
among Hispanics/Latinos but not among
non-Hispanic whites.
Table 3 illustrates the model of ad-
justments of mean HbA1c according to
covariates included in the combined
model and by racial/heritage group.
The largest changes in mean HbA1c oc-
curred after adjustment for age, FPG,
and 2hPG.
CONCLUSIONS
The observations described in this anal-
ysis both confirm previous findings and
offer new light on population-based
differences in HbA1c. Compared with
Hispanics/Latinos (as a group), non-
Hispanic whites demonstrated signifi-
cantly lower adjusted mean HbA1c levels
within each glycemic category. The
difference in adjustedmean HbA1c level
between non-Hispanic whites and
Hispanics/Latinos ranged from 0.08 to
0.24% (NGSP units) across diabetes sta-
tus categories. Mean adjusted HbA1c
levels also varied among Hispanic/La-
tino heritage groups, with differences
ranging from 0.04 to 0.25% (NGSP units)
across diabetes status categories. The
largest difference in mean adjusted
HbA1c (between non-Hispanic whites
and Hispanics/Latinos and among His-
panic/Latino heritage groups or across
the seven groups) was observed in the
unrecognized diabetes category. Nei-
ther the difference in HbA1c between
non-Hispanic whites and Hispanics/Lati-
nos nor the differences among the His-
panic/Latino heritage groups could be
explained by controlling for age, sex,
BMI, plasma glucose, or hematologic
or biochemical covariates. To the best
of our knowledge, these are new find-
ings that have not been described and
compared before in a large sample of
U.S. Hispanic/Latino adults of diverse
heritage groups.
Our results confirm that there are sta-
tistically significant differences in mean
HbA1c levels between Hispanics/Latinos
(as a unitary group) and non-Hispanic
whites with NGT, prediabetes, and un-
recognized diabetes after adjustment for
age, sex, BMI, FPG, 2hPG, FSI, Hgb, MCV,
Figure 1—Error bars represent 95% CIs. The covariates included sex, age, BMI, FPG, 2hPG, FSI,
Hgb, MVC, SBP, DBP, ALT, AST, and GGT. The HCHS/SOL data were collected fromMarch 2008 to
June 2011, and NHANES data were collected from 2007 to 2012. NHW, non-Hispanic white.
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SBP, and hepatic enzymes, as previously
demonstrated in NHANES (9), the Dia-
betes Prevention Program (10), and by
Hermanetal. (11). In addition,weobserved
that HbA1c had a direct relationship with
age, as demonstrated in the Framingham
Offspring Study and the NHANES (21).
Important strengths of our study in-
clude the diversity of Hispanic/Latino
heritage groups and the large sample
sizedin both the HCHS/SOL and the
NHANESdwhich provides more reliable
estimates for HbA1c, the ability to exclude
individualswhohad conditions thatmight
impact the relationship between HbA1c
and the selected covariates, and ade-
quate power to assess statistical differ-
ences among Hispanic/Latino heritage
groups and non-Hispanic whites accord-
ing to diabetes status categories.
The evaluation of differences in HbA1c
levels should also be cautiously inter-
preted from a racial/ethnic perspective.
The terms “non-Hispanic white” and
“Hispanic/Latino” give the impression
that these two demographic groups
are distinct races or ethnicities and
that each Hispanic/Latino heritage
group constitutes a separate racial or
ethnic entity. These interpretations as-
sume that race is a purely biological clas-
sification of human ancestry/origins,
and not a sociocultural construct (22);
fail to acknowledge that Hispanics/
Latinos could be of any race; and could
mislead the interpretation of the obser-
vations by attributing differences exclu-
sively to ancestry. On the other hand,
the genetics of Hgb glycation have not
been fully described but are currently
being studied (23–25). Genetic analyses
of HbA1c and other select variables as-
sessed during the baseline examination
are currently in progress and will be
published separately.
The differences in covariate-adjusted
mean HbA1c levels among Hispanics/La-
tinos or between Hispanics/Latinos and
non-Hispanic whites could be inter-
preted in the light of mediators that
were not evaluated. For instance, condi-
tions that increase or decrease red cell
turnover, including Hgb variants and he-
moglobinopathies (26), history of blood
transfusion (27) or blood loss, or other
blood or coagulation disorders were not
evaluated as part of the baseline ex-
amination in the HCHS/SOL. Differences
in red blood cell morphology (28), red
cell life span (29–31) or Hgb glucose
affinity and glycation (28,31,32), iron de-
ficiency and iron deficiency anemia (33),
and obstructive sleep apnea (34,35),
among other factors, may have also me-
diated the observed differences. Some
of these factors may not be intrinsically
related to a specific Hispanic/Latino
genetic or cultural heritage but may de-
pend on cumulative nutritional, socio-
economic, and medical history (36)
and on local community resources or
exposures. In addition, although both
the reliability and repeatability of the
HbA1c assay in the study were high, the
analyses presented in this report only
represent a one-time assessment corre-
lation and not repeated measurements
over time.
Existing HbA1c assays can only detect
levels within one decimal place of per-
cent unit based on the NGSP (37).
Hence, the clinical implications of the
differences in HbA1c to two decimal pla-
ces observed in our analysis are un-
known. The precision of the observed
statistically significant differences in ad-
justed mean HbA1c levels in the NGT and
prediabetes categories would not be de-
tected in a clinical assay, and a diagnos-
tic or therapeutic decision might not
be pursued. In contrast, adjusted mean
HbA1c level in the unrecognized diabe-
tes category would be detected and
considered sufficient to prompt diag-
nostic or therapeutic decisions.
Similarly, the clinical significance of
the observed differences in HbA1c in
our analysis for long-term diabetes-
related complications is unknown. In the
UK Prospective Diabetes Study (UKPDS),
every 1% NGSP unit reduction in HbA1c
was associated with a 37% reduction in
microvascular complications and 43%
reduction in amputations and mortality
associated with peripheral vascular dis-
ease (38). In the Diabetes Control and
Complications Trial (DCCT), a sustained
difference in HbA1c of 1.9% NGSP units
between patients with type 1 diabetes
on intensive insulin therapy and pa-
tients on conventional insulin therapy
was associated with a 76% risk reduction
in the onset of retinopathy and 34% risk
reduction in the onset of microalbumi-
nuria (39). Further reduction in HbA1c to
thenormal range (e.g., 6.0%)was expected
to be associated with additional risk re-
duction in the onset and progression of
retinopathy (40). However, the clinical
significance of the smaller differences in
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HbA1c (e.g., 0.25% and 0.39%) observed
between Hispanics/Latinos and non-
Hispanic whites with unrecognized dia-
betes in this study is unknown. These
differences are not the result of an inter-
vention to reduce glycemic levels and
may not reflect differences in glycemia,
since mean HbA1c levels were adjusted
for FPG and 2hPG. Since HCHS/SOL
participants have been followed annu-
ally and a second examination is being
conducted, assessmentof risk for diabetes
and macro- and microvascular complica-
tions associated with baseline and follow-
up HbA1c will be possible in the future.
The findings presented in this analysis
suggest that statistically significant dif-
ferences in HbA1c exist between His-
panics/Latinos and non-Hispanic whites
and among different Hispanic/Latino
heritage groups. The mechanisms and
clinical implications behind these differ-
ences need to be further investigated.
Understanding the relationship be-
tween HbA1c and nonglycemic factors
and incorporating them into the inter-
pretation of HbA1c tests may prove valu-
able to the diagnosis of diabetes and
monitoring glycemic control of Hispanics/
Latinos.
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